GlassScriptPhysician profile
Kimberly Lehman
NPI 1932320397
$10,107.69
in general payments reported to CMS, 2019-2025
26 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $286 · 2021: $1,165 · 2022: $2,000 · 2023: $2,068 · 2024: $1,669 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,538 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,537.60 |
| Education | $378.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,882.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,339.70 | 2020-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $1,268.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,024.11 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $795.56 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $650.38 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $543.42 | 2019-2025 | |
| Amgen INC. | $518.70 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $482.76 | 2019-2025 | Nemluvio, Dysport, Aklief |
| E.R. Squibb & Sons, L.L.C. | $482.54 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $257.05 | 2020-2024 | Jublia, Arazlo |
| Ucb, INC. | $256.65 | 2021-2025 | Bimzelx, Cimzia |
| Allergan, INC. | $104.27 | 2019-2020 | |
| Journey Medical Corporation | $100.46 | 2019-2023 | |
| Incyte Corporation | $78.83 | 2023-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $67.63 | 2025 | |
| Genzyme Corporation | $42.95 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $41.39 | 2020-2021 | |
| Almirall LLC | $33.75 | 2019 | |
| Botanix Sb INC | $33.06 | 2025 | Sofdra |
| Lnhc, INC | $22.54 | 2025 | Zelsuvmi |
| Biofrontera INC. | $20.77 | 2025 | |
| Leo Pharma INC. | $18.42 | 2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $15.93 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Strata Skin Sciences, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.